Log In
Print
BCIQ
Print
Print this Print this
 

AGT-182

  Manage Alerts
Collapse Summary General Information
Company ArmaGen Inc.
DescriptionIduronate-2-sulfatase (IDS) using Trojan horse technology
Molecular Target
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPhase I
Standard IndicationMucopolysaccharidosis
Indication DetailsTreat mucopolysaccharidosis II (MPS II, Hunter syndrome)
Regulatory Designation

U.S. - Orphan Drug (Treat mucopolysaccharidosis II (MPS II, Hunter syndrome));
EU - Orphan Drug (Treat mucopolysaccharidosis II (MPS II, Hunter syndrome))

Partner

Shire plc


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$225.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today